Patents by Inventor Jesus Cortes
Jesus Cortes has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20190291042Abstract: The present invention relates to a method and system for separating CO2 based on regenerative chemical absorption, including an absorber where the CO2 remains retained in an absorbent liquid, and including a regenerator where the CO2 is released, obtaining a regenerated absorbent that is re-used in the absorption unit. The invention proposes a configuration of the entire capturing process which allows an efficient operation that significantly reduces the energy requirements mainly associated with the regeneration of the absorbent, as well as a lesser thermal degradation of same.Type: ApplicationFiled: June 19, 2017Publication date: September 26, 2019Inventors: Fernando VEGA BORRERO, Benito NAVARRETE RUBIA, Jose Antonio CAMINO FERNANDEZ, Mercedes CANO PALACIOS, Vicente Jesus CORTES GALEANO
-
Patent number: 9006392Abstract: Described are lantibiotic-based compounds, pharmaceutical compositions comprising the same and use of the compounds and said compositions, for the treatment of microbial infection, for example Clostridium difficile or Micrococcus luteus infection. The lantibiotic-based compounds have antimicrobial activity and in comparison to one or more of actagardine, actagardine B, deoxyactagardine B and deoxyactagardine have retained activity or improved activity.Type: GrantFiled: February 1, 2011Date of Patent: April 14, 2015Assignee: Novacta Biosystems LimitedInventors: Michael John Dawson, Antony Nicholas Appleyard, Jesus Cortes Bargallo, Sjoerd Nicolaas Wadman
-
Patent number: 8575094Abstract: A method for the treatment or prophylaxis of a microbial infection of the lower intestine or colon in a subject is described, wherein the method comprises administration to the subject of a type-B lantibiotic, wherein the type-B lantibiotic may include compounds selected from the group consisting of mersacidin, actagardine, plantaricin, planosporicin, ruminococcin, antibiotic 10789, michiganin and haloduracin, and derivatives and variants thereof.Type: GrantFiled: January 21, 2009Date of Patent: November 5, 2013Assignee: Novacta Biosystems LimitedInventors: Sjoerd Nicolaas Wadman, Michael John Dawson, Jesus Cortes Bargallo
-
Patent number: 8465947Abstract: Characterization of the biosynthetic gene cluster for the lantibiotic antibiotic actagardine, identification of a novel variant of actagardine and its biosynthetic cluster, and methods of production and use of actagardine, a novel actagardine variant, herein referred to as actagardine B, and variants of both of these produced according to this invention, utilizing genes from the characterized biosynthetic gene clusters, is described.Type: GrantFiled: June 10, 2011Date of Patent: June 18, 2013Assignee: Novacta Biosystems LimitedInventors: Steven Boakes, Jesus Cortes Bargallo, Michael John Dawson
-
Publication number: 20120302728Abstract: Described are lantibiotic-based compounds, pharmaceutical compositions comprising the same and use of the compounds and said compositions, for the treatment of microbial infection, for example Clostridium difficile or Micrococcus luteus infection. The lantibiotic-based compounds have antimicrobial activity and in comparison to one or more of actagardine, actagardine B, deoxyactagardine B and deoxyactagardine have retained activity or improved activity.Type: ApplicationFiled: February 1, 2011Publication date: November 29, 2012Inventors: Michael John Dawson, Antony Nicholas Appleyard, Jesus Cortes Bargallo, Sjoerd Nicolaas Wadman
-
Patent number: 8183202Abstract: A method for the treatment or prophylaxis of a microbial infection of the lower intestine or colon in a subject is described, wherein the method comprises administration to the subject of a type-B lantibiotic, wherein the type-B lantibiotic may include compounds selected from the group consisting of mersacidin, actagardine, plantaricin, planosporicin, ruminococcin, antibiotic 10789, michiganin and haloduracin, and derivatives and variants thereof.Type: GrantFiled: January 21, 2009Date of Patent: May 22, 2012Assignee: Novacta Biosystems LimitedInventors: Sjoerd Nicolaas Wadman, Michael John Dawson, Jesus Cortes Bargallo
-
Publication number: 20110306091Abstract: This invention relates to characterisation of the biosynthetic gene cluster for the lantibiotic actagardine, identification of a novel variant of actagardine and its biosynthetic cluster, and methods of production and use of actagardine, a novel actagardine variant, herein referred to as actagardine B, and variants of both of these produced according to this invention, utilizing genes from the characterised biosynthetic gene clusters.Type: ApplicationFiled: June 10, 2011Publication date: December 15, 2011Applicant: Novacta Biosystems LimitedInventors: Steven Boakes, Jesus Cortes Bargallo, Michael John Dawson
-
Patent number: 7989416Abstract: Characterization of the biosynthetic gene cluster for the lantibiotic actagardine, identification of a novel variant of actagardine and its biosynthetic cluster, and methods of production and use of actagardine are described.Type: GrantFiled: January 17, 2007Date of Patent: August 2, 2011Assignee: Novacta Biosystems LimitedInventors: Steven Boakes, Jesus Cortes Bargallo, Michael John Dawson
-
Patent number: 7807418Abstract: A hybrid type I polyketide synthase gene typically containing a starter module and a plurality of heterologous extender modules is used to synthesise novel polyketides. It is preferably under the control of type II polypolyketide synthase promoter e.g. act I or S. coelicolor.Type: GrantFiled: July 12, 2004Date of Patent: October 5, 2010Assignee: Biotica Technology LimitedInventors: Peter Francis Leadlay, James Staunton, Jesus Cortes
-
Publication number: 20100048459Abstract: This invention relates to characterisation of the biosynthetic gene cluster for the lantibiotic actagardine, identification of a novel variant of actagardine and its biosynthetic cluster, and methods of production and use of actagardine, a novel actagardine variant, herein referred to as actagardine B, and variants of both of these produced according to this invention, utilizing genes from the characterised biosynthetic gene clusters.Type: ApplicationFiled: January 17, 2007Publication date: February 25, 2010Inventors: Steven Boakes, Jesus Cortes Bargallo, Michael John Dawson
-
Patent number: 7592308Abstract: The present invention relates to methods and products for improved production of the lantibiotic mersacidin. There is provided a method of producing a mersacidin variant which comprises introducing into a cell which is a ?MrsA host cell an expression vector encoding said variant, and recovering said variant from the cell culture. Preferred variants include the novel variants of Table 1, e.g. mersacidin F3W, said mersacidin F3W optionally having a further one or more variations, e.g. mersacidin F3W G8A. Also provided is a Bacillus cell which is a SigH deficient strain of Bacillus sp. HIL Y-85,54728 (NCIMB Accession Number NCIMB 41211); this cell may also be used in the production of mersacidin and its variants. Further aspects of the invention include a DNA cassette which comprises a nucleotide sequence encoding the mersacidin mrsA propeptide, and a method to transform a Bacillus HIL host cell with plasmid, which method includes the step of electroporation.Type: GrantFiled: September 25, 2006Date of Patent: September 22, 2009Assignee: Novacta Biosystems LimitedInventors: Michael John Dawson, Jesus Cortes Bargallo, Antony Nicholas Appleyard, Brian Arthur Michael Rudd, Steven Boakes, Gabriele Bierbaum, Anja Hoffmann, Stephanie Schmitz
-
Publication number: 20090203583Abstract: The present invention provides methods for the treatment or prophylaxis of a microbial infection of the lower intestine or colon in a subject, the method comprising administering to the subject a type-B lantibiotic. In particular, the invention provides methods for the treatment or prophylaxis of a Clostridium difficile infection. The type-B lantibiotics may include compounds selected from the group consisting of mersacidin, actagardine, plantaricin, planosporicin, ruminococcin, antibiotic 10789, michiganin and haloduracin, and derivatives and variants thereof.Type: ApplicationFiled: January 21, 2009Publication date: August 13, 2009Applicant: Novacta Biosystems LimitedInventors: Sjoerd Nicolaas Wadman, Michael John Dawson, Jesus Cortes Bargallo
-
Publication number: 20070117749Abstract: The present invention relates to methods and products for improved production of the lantibiotic mersacidin. There is provided a method of producing a mersacidin variant which comprises introducing into a cell which is a ?MrsA host cell an expression vector encoding said variant, and recovering said variant from the cell culture. Preferred variants include the novel variants of Table 1, e.g. mersacidin F3W, said mersacidin F3W optionally having a further one or more variations, e.g. mersacidin F3W G8A. Also provided is a Bacillus cell which is a SigH deficient strain of Bacillus sp. HIL Y-85,54728 (NCIMB Accession Number NCIMB 41211); this cell may also be used in the production of mersacidin and its variants. Further aspects of the invention include a DNA cassette which comprises a nucleotide sequence encoding the mersacidin mrsA propeptide, and a method to transform a Bacillus HIL host cell with plasmid, which method includes the step of electroporation.Type: ApplicationFiled: September 25, 2006Publication date: May 24, 2007Applicant: Novacta Biosystems LimitedInventors: Michael Dawson, Jesus Cortes Bargallo, Antony Appleyard, Brian Rudd, Steven Boakes, Gabriele Bierbaum, Anja Hoffmann, Stephanie Schmitz
-
Patent number: 7198922Abstract: A polyketide synthase (“PKS”) of Type I is a complex multienzyme including a loading domain linked to a multiplicity of extension domains. The first extension module receives an acyl starter unit from the loading domain and each extension module adds a further ketide unit which may undergo processing (e.g. reduction). We have found that the Ksq domain possessed by some PKS's has decarboxylating activity, e.g. generating (substituted) acyl from (substituted) malonyl. The CLF domain of type II PKS's has similar activity. By inserting loading modules including such domains into PKS's not normally possessing them it is possible to control the starter units used.Type: GrantFiled: February 19, 2004Date of Patent: April 3, 2007Assignees: Biotica Technology Limited, Pfizer, Inc.Inventors: Peter Francis Leadlay, James Staunton, Jesus Cortes, Hamish Alastair Irvine McArthur
-
Patent number: 7148045Abstract: A polyketide synthase (“PKS”) of Type I is a complex multienzyme including a loading domain linked to a multiplicity of extension domains. The first extension module receives an acyl starter unit from the loading domain and each extension module adds a further ketide unit which may undergo processing (e.g. reduction). We have found that the Ksq domain possessed by some PKS's has decarboxylating activity, e.g. generating (substituted) acyl from (substituted) malonyl. The CLF domain of type II PKS's has similar activity. By inserting loading modules including such domains into PKS's not normally possessing them it is possible to control the starter units used.Type: GrantFiled: June 29, 1999Date of Patent: December 12, 2006Assignee: Biotica Technology LimitedInventors: Peter Francis Leadlay, James Staunton, Jesus Cortes, Hamish Alastair Irvine McArthur
-
Publication number: 20060240528Abstract: A polyketide synthase (“PKS”) of Type I is a complex multienzyme including a loading domain linked to a multiplicity of extension domains. The first extension module receives an acyl starter unit from the loading domain and each extension module adds a further ketide unit which may undergo processing (e.g. reduction). We have found that the Ksq domain possessed by some PKS's has decarboxylating activity, e.g. generating (substituted) acyl from (substituted) malonyl. The CLF domain of type II PKS's has similar activity. By inserting loading modules including such domains into PKS's not normally possessing them it is possible to control the starter units used.Type: ApplicationFiled: April 21, 2006Publication date: October 26, 2006Inventors: Peter Leadlay, James Staunton, Jesus Cortes, Hamish Irvine McArthur
-
Patent number: 6960453Abstract: A hybrid type I polyketide synthase gene typically containing a starter module and a plurality of heterologous extender modules is used to synthesize novel polyketides. It is preferably under the control of a type II polypolyketide synthase promoter e.g. act I of S. coelicolor.Type: GrantFiled: July 4, 1997Date of Patent: November 1, 2005Assignee: Biotica Technology LimitedInventors: Peter Francis Leadlay, James Staunton, Jesus Cortes
-
Publication number: 20050089982Abstract: A hybrid type I polyketide synthase gene typically containing a starter module and a plurality of heterologous extender modules is used to synthesise novel polyketides. It is preferably under the control of type II polypolyketide synthase promoter e.g. act I or S.coelicolor.Type: ApplicationFiled: July 12, 2004Publication date: April 28, 2005Inventors: Peter Leadlay, James Staunton, Jesus Cortes
-
Publication number: 20050090461Abstract: A polyketide synthase (“PKS”) of Type I is a complex multienzyme including a loading domain linked to a multiplicity of extension domains. The first extension module receives an acyl starter unit from the loading domain and each extension module adds a further ketide unit which may undergo processing (e.g. reduction). We have found that the Ksq domain possessed by some PKS's has decarboxylating activity, e.g. generating (substituted) acyl from (substituted) malonyl. The CLF domain of type II PKS's has similar activity. By inserting loading modules including such domains into PKS's not normally possessing them it is possible to control the starter units used.Type: ApplicationFiled: February 19, 2004Publication date: April 28, 2005Inventors: Peter Leadlay, James Staunton, Jesus Cortes, Hamish McArthur
-
Patent number: RE45003Abstract: Characterization of the biosynthetic gene cluster for the lantibiotic actagardine, identification of a novel variant of actagardine and its biosynthetic cluster, and methods of production and use of actagardine are described.Type: GrantFiled: December 4, 2012Date of Patent: July 8, 2014Assignee: Novacta Biosystems LimitedInventors: Steven Boakes, Jesus Cortes Bargallo, Michael John Dawson